Skip to main content

Published locations for Transitioning regimen may prolong proteasome inhibitor–based therapy for MM

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Transitioning regimen may prolong proteasome inhibitor–based therapy for MM

User login

  • Reset your password
  • /content/transitioning-regimen-may-prolong-proteasome-inhibitor-based-therapy-mm
  • /fedprac/article/225200/multiple-myeloma/transitioning-regimen-may-prolong-proteasome-inhibitor-based
  • /hematologynews/article/225200/multiple-myeloma/transitioning-regimen-may-prolong-proteasome
  • /internalmedicinenews/article/225200/multiple-myeloma/transitioning-regimen-may-prolong-proteasome
  • /oncologypractice/article/225200/multiple-myeloma/transitioning-regimen-may-prolong-proteasome
  • /fedprac/avaho/article/225200/multiple-myeloma/transitioning-regimen-may-prolong-proteasome-inhibitor
  • /hematology-oncology/article/225200/multiple-myeloma/transitioning-regimen-may-prolong-proteasome
  • /internalmedicine/article/225200/multiple-myeloma/transitioning-regimen-may-prolong-proteasome